Jennifer L. Spratlin
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Pancreatic and Hepatic Oncology Research, Gastric Cancer Management and Outcomes, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics
Most-Cited Works
- → Clinical Applications of Metabolomics in Oncology: A Review(2009)741 cited
- → Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2(2010)552 cited
- → Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study(2017)506 cited
- → The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma(2004)425 cited
- → Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).(2014)231 cited
- → Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study(2018)176 cited
- → Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).(2014)139 cited
- → A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors(2015)127 cited
- → Pharmacogenetics of paclitaxel metabolism(2006)121 cited
- → Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer(2006)121 cited